QHSLab Reports 127% ISP Revenue Growth and Launches GLP-1 Support Program
summarizeSummary
QHSLab announced unaudited Q1 2026 ISP revenue of $370,000, representing 127% year-over-year growth, and launched its new Q-Connect GLP-1 Support Assessment program.
check_boxKey Events
-
Strong Q1 2026 ISP Revenue Growth
The company reported unaudited Integrated Service Program (ISP) revenue of $370,000 for Q1 2026, marking a 127% increase from $163,000 in Q1 2025.
-
Launches Q-Connect GLP-1 Support Assessment
QHSLab introduced a new Q-Connect GLP-1 Support Assessment and Personalized Health Journeys Program, designed to assist patients using anti-obesity medications (AOMs), including GLP-1 therapies, and those aiming to improve cardiometabolic health.
auto_awesomeAnalysis
QHSLab, a digital health company, reported substantial unaudited Q1 2026 revenue growth of 127% year-over-year in its Integrated Service Program (ISP), reaching $370,000. This significant growth for a company of its size indicates strong operational momentum and increasing adoption of its digital care model. Additionally, the launch of the Q-Connect GLP-1 Support Assessment positions the company in a high-demand and rapidly expanding market segment, potentially broadening its recurring care opportunities and strengthening patient engagement in cardiometabolic and behavioral health.
At the time of this filing, USAQ was trading at $0.60 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.08 to $1.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.